Core Insights - The article highlights two lesser-known S&P 500 stocks, Synopsys and Hologic, that present significant growth potential despite their current market challenges [1]. Synopsys (NASDAQ: SNPS) - Synopsys has shown resilience with an 8% year-to-date increase in stock price, closing at $528, despite a nearly 5% decline over the past year [2][3]. - The company reported revenue of $1.64 billion for the quarter ending October 24, marking an 11% year-over-year growth, with earnings per share at $7.15, reflecting a more than 200% increase [3]. - Synopsys is pursuing a $35 billion acquisition of Ansys, expected to close in early 2025, which could enhance its market position pending regulatory approvals [4]. - The increasing complexity of semiconductor design, driven by AI, machine learning, and IoT, is expected to boost demand for Synopsys' Electronic Design Automation tools [5]. - Analysts at TipRanks have set a 12-month price target of $630 for Synopsys, indicating a potential upside of 20%, with targets ranging from $540 to $690 [6]. Hologic (NASDAQ: HOLX) - Hologic operates in the medical technology sector, focusing on breast health and diagnostics, and has a strong portfolio despite being overshadowed by larger healthcare companies [8]. - The company is well-positioned to benefit from an aging population and the growing emphasis on early disease detection and personalized medicine [9]. - Hologic's collaboration with the CDC to develop reagents for detecting H5N1 bird flu highlights its capability to scale testing rapidly during public health crises [10]. - The stock price for Hologic ended at $64.27, down 0.6%, with a year-to-date decline of 10% [11]. - Analysts project a potential rally of over 30% for Hologic, with an average price target of $83.54 within the next 12 months, ranging from $75 to $90 [12].

Core Insights - Hologic (HOLX) is experiencing growth from new strategic product launches in Diagnostics and Breast Health, but macroeconomic challenges and unfavorable foreign exchange impacts are hindering its overall growth [1][8] Growth Drivers - The molecular diagnostic assays segment is a significant revenue contributor, accounting for 11% of revenues in Q1 fiscal 2025, excluding COVID-19 sales [2] - The company's BV CV/TV assay has shown strong double-digit growth, and the Biotheranostics lab testing business is also contributing positively [2] - Hologic's core women's health assays on the Panther platform performed robustly during the quarter [2] - The new Envision Mammography Platform, which offers a 2.5-second scan time, is set for commercial launch next year [3] - The next-generation Genius AI Detection PRO solution aims to enhance accuracy and efficiency in cancer screening, addressing racial bias concerns in AI-driven breast cancer diagnosis [4] International Expansion - Hologic's Surgical business is expanding into new global markets, with the International Surgical business reporting over 20% growth in Q1 fiscal 2025 [5] - The company is increasing the global reach of the Panther Fusion system to meet the demand for high-throughput molecular diagnostic respiratory testing [5] Operational Strategies - Hologic is streamlining operations and reducing costs through strategic investments in areas with good returns, such as the Genius marketing campaign and cervical cancer co-testing initiatives [6] Financial Performance - The stock has declined 13.2% over the past year, while the industry has risen by 5.2%, but there are expectations for the stock to regain momentum with the expansion of diagnostics and breast health offerings [7] - Hologic has reduced its full-year revenue guidance by $100 million to a range of $4.05 billion to $4.10 billion due to macroeconomic uncertainties and supply constraints [8] Challenges - The company faces challenges from potential long-term recession impacts, global supply constraints, and increased costs in manufacturing and transportation [8][9] - Hologic anticipates lower Breast Health capital equipment sales this year due to an overly aggressive initial forecast [10] - The strengthening U.S. dollar is expected to create a $20 million foreign currency headwind for fiscal 2025, a significant change from earlier expectations [11]

Core Insights - Hologic, Inc. has shown strong performance in its molecular diagnostics segment, but faces challenges from declining COVID-19 sales and a tough macroeconomic environment [1][7][8] Financial Performance - Hologic has a market capitalization of $14.47 billion and has beaten earnings estimates in three of the last four quarters, with an average surprise of 2.53% [2] - The company has reduced its full-year revenue guidance by $100 million to a range of $4.05-$4.10 billion, anticipating lower Breast Health capital equipment sales [9] Segment Performance - The molecular diagnostics segment contributed 11% to first-quarter fiscal 2025 revenues, excluding COVID-19 sales, with strong growth in the BV CV/TV assay and core women's health assays [4] - The Panther platform's adoption is increasing, with nearly 40% of U.S. customers utilizing the system as of the fiscal first quarter [4] Strategic Initiatives - Hologic has implemented strategic initiatives to streamline operations and reduce costs, including investments in marketing campaigns and competitive market share efforts [5] - The company received the Innovative Technology Contract from Vizient, which expands access to its surgical product lineup [6] Market Challenges - The decline in COVID-19 assay revenues is expected to restrain diagnostics sales growth to mid-single digits for fiscal 2025 [7] - Macroeconomic concerns, including potential recession impacts and global supply constraints, are affecting the company's ability to meet customer demand and increasing operational costs [8]

Core Insights - Hologic's international operations are crucial for understanding its financial strength and growth potential [1][2] - The company's reliance on overseas markets provides insights into its earnings durability and growth capabilities [2][3] Revenue Performance - Total revenue for the recent quarter reached $1.02 billion, reflecting a 0.9% increase from the prior-year quarter [4] - Revenue contributions from international markets showed notable trends, with Rest of World generating $55.2 million (5.40% of total revenue), Europe contributing $148.9 million (14.57%), and Asia-Pacific at $59.8 million (5.85%) [5][6][7] Regional Revenue Breakdown - Rest of World revenue exceeded consensus estimates by 0.31%, compared to $50.9 million (5.15%) in the previous quarter and $52.8 million (5.21%) in the same quarter last year [5] - Europe outperformed expectations by 8.27%, with a significant increase from $125 million (12.65%) in the previous quarter and $142.8 million (14.10%) in the same quarter last year [6] - Asia-Pacific revenue fell short of projections by 8.35%, with a decrease from $66.4 million (6.72%) in the previous quarter and an increase from $63.8 million (6.30%) in the year-ago quarter [7] Future Projections - Analysts project total revenue of $1 billion for the current fiscal quarter, a decline of 1.6% year-over-year, with expected contributions of 5.6% from Rest of World, 13.6% from Europe, and 6.6% from Asia-Pacific [8] - For the full year, total revenue is anticipated to reach $4.08 billion, reflecting a 1.3% increase from the previous year, with expected contributions of 5.5% from Rest of World, 13.5% from Europe, and 6.5% from Asia-Pacific [9] Strategic Considerations - Hologic's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of international revenue trends to project future directions [10] - Analysts emphasize the importance of various factors, including local market status, in shaping revenue forecasts [11]

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks likely to outperform the market in the short term [2][3] - Each stock is rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Score identifies attractive and discounted stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score helps investors capitalize on price trends by analyzing short-term price changes and earnings estimate revisions [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking stocks with strong value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors in building successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: Hologic Inc. (HOLX) - Hologic Inc. is a medical technology company focused on women's health, currently holding a Zacks Rank of 3 (Hold) and a VGM Score of B [11] - The company has seen upward revisions in earnings estimates, with the Zacks Consensus Estimate for fiscal 2025 at $4.28 per share, and an average earnings surprise of 2.5% [12]

Washington, D.C. 20549 __________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 28, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-36214 __________________________________________________________ HO ...

Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of $1.03 in the first quarter of fiscal 2025, up 5.1% year over year. The metric surpassed the Zacks Consensus Estimate by 0.9%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs and many others. The company’s GAAP EPS was 87 cents in the quarter compared with $1.03 in the ...

Hologic, Inc. (NASDAQ:HOLX) Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Mike Watts - Corporate Vice President, IR Steve MacMillan - Chairman, President and CEO Essex Mitchell - COO Karleen Oberton - CFO Conference Call Participants Patrick Donnelly - Citi Anthony Petrone - Mizuho Group Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Tycho Peterson - Jefferies Casey Woodring - JP Morgan Tejas Savant - Morgan Stanley Ryan Zimmerman - BTIG Jack Meehan - Nephron R ...

Hologic (HOLX) reported $1.02 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 0.9%. EPS of $1.03 for the same period compares to $0.98 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.02 billion, representing no surprise. The company delivered an EPS surprise of +0.98%, with the consensus EPS estimate being $1.02.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...

Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.98%. A quarter ago, it was expected that this medical device maker would post earnings of $1.02 per share when it actually produced earnings of $1.01, delivering a surprise of -0.98%.Over the last four quarters, the comp ...